Last reviewed · How we verify
NCT06855966
Feasibility of ETCO₂ Changes During Passive Leg Raise for Fluid Management in Lung Surgery
NA trial testing 250 ml crystalloid bolus infusion in Lung Cancer in 53 participants. Completed in 15 March 2021.
14 March 2021
Quick facts
| Lead sponsor | Istanbul University - Cerrahpasa |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | diagnostic |
| Enrollment | 53 |
| Start date | 4 August 2020 |
| Primary completion | 14 March 2021 |
| Estimated completion | 15 March 2021 |
| Sites | 1 location across Turkey (Türkiye) |
Drugs / interventions tested
- 250 ml crystalloid bolus infusion
Conditions studied
- Lung Cancer — all drugs for Lung Cancer →
Sponsor
Istanbul University - Cerrahpasa
Who can join
18 and older, any sex, with Lung Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Aim: End tidal carbondioxide pressure (EtCO2) is an indirect indicator of cardiac output (CO) which is monitored in every patient at perioperative setting. The investigators aimed to use increase of EtCO2 as a response to passive leg raising maneuver (PLR) to indicate fluid responsiveness in patients who underwent lung resection with video-assisted thoracoscopic surgery (VATS).
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
End-tidal CO<sub>2</sub> response to passive leg raise for fluid management in lung resections: A randomized controlled trial.
Uzan HSA, Yuceyar L, Sayilgan NC. · · 2025 · PMID 41450995 · DOI 10.12669/pjms.41.12.12679
Verify or expand the search:
- PubMed search for NCT06855966
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Lung Cancer
Currently open trials in the same condition.
- NCT07295821 — Osimertinib Induction and Maintenance for Chemo-ineligible Stage III Unresectable EGFR+ NSCLC: Single-arm Study · Phase 2 · recruiting
- NCT06909201 — Hyperpolarized Xenon-129 Magnetic Resonance Imaging in Lung Cancer Patients Receiving Radiation Therapy for Investigatin · Phase 1 · recruiting
- NCT07524114 — Study of High-Precision Evaluation of Molecular ResiduaL Disease Through a PlatfOrm for Cancer TracKing and Interception · recruiting
- NCT07487064 — Galvanize Aliya® EX Pulsed Electric Field (PEF) Treat and Resect Study · NA · recruiting
- NCT07146568 — Evaluating the Implementation and Effectiveness of the Pink and Pearl Campaign on Lung Cancer Screening at Christian Hos · NA · recruiting
Other Istanbul University - Cerrahpasa trials
Trials by the same sponsor.
- NCT07588685 — Validity and Reliability of the Turkish Form of the Enjoyment of Physical Activity Scale-8 in Geriatrics With Minimal Co · not yet recruiting
- NCT07370025 — The Effect of Lullaby During Bath Time on Mother-Infant Bonding, Postpartum Depression, and Parental Self-Efficacy in In · NA · not yet recruiting
- NCT07378449 — The Effect of Hand Exercise Hoops on Labour Pain · NA · not yet recruiting
- NCT07293000 — Evaluating Two Nursing Interventions to Prevent Urinary Retention After Spinal Anesthesia · NA · not yet recruiting
- NCT07562880 — Validity and Reliability of the Exercise-Related Health Beliefs Attitude Scale in Geriatric Individuals · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06855966 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Istanbul University - Cerrahpasa
- Last refreshed: 4 March 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06855966.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing